AbbVie: New Data Shows Potential Of ABT-493, ABT-530 In Hepatitis C Genotypes

(RTTNews) - AbbVie (ABBV) reported that with eight weeks of treatment in Phase 2 SURVEYOR-1 and SURVEYOR-2 studies, 97-98 percent of genotype 1-3 chronic hepatitis C virus infected patients without cirrhosis treated with the company's investigational ribavirin-free, pan-genotypic regimen of ABT-493 and ABT-530 achieved sustained virologic response at 12 weeks post-treatment. Additionally, 100 percent of genotype 4, 5 or 6 chronic HCV infected patients without cirrhosis achieved sustained virologic response with 12 weeks of treatment.

In separate data from the SURVEYOR-2 study, 100 percent of genotype 3 chronic HCV infected patients with compensated cirrhosis new to therapy achieved sustained virologic response with 12 weeks of treatment both with and without ribavirin.

ABT-493 is Enanta's second protease inhibitor being developed through its collaboration with AbbVie and is one of the two new direct-acting antivirals in the combination treatment being investigated in the ongoing SURVEYOR-1 and SURVEYOR-2 studies.